Mutation burden in conjunction with MAPK-pathway mutation status as a prognostic biomarker of overall melanoma survival.

9584Background: The high tumor mutation burden (TMB) in melanoma triggers the increased presentation of neoantigens, which are required to elicit an immune response. As a result, TMB has been propo...